News
1d
Pharmaceutical Technology on MSNBeOne Medicines’ BTK degrader gains EMA PRIME designationThe designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
8d
DPA International on MSNEMA recommends approval of additional Alzheimer's treatmentThe European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.
5d
Pharmaceutical Technology on MSNGilead wins positive European approval opinion for twice-yearly HIV injectionThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...
The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.
European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
Sarepta ( SRPT) will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the U.S. Food and Drug ...
The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant. About Hematopoietic stem cell transplant-associated thrombotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results